Brought to you by 
Innovative Metabolics signs pact for CRTX's device IP
01 Feb 2007
Executive Summary
Critical Therapeutics (CRTX; respiratory, inflammatory, and critical care diseases) has licensed private pharma Innovative Metabolics (IMI) exclusive worldwide rights to patents covering a neurostimulation device for inflammation.
Deal Industry
- Biotechnology
- Medical Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Innovative Metabolics signs pact for CRTX's device IP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice